Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Alkermes NASDAQ: ALKS executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for a planned leadership transition.
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises
ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.
Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company
Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales rising to $338.1M, with LUMRYZ contributing $39.5M post-acquisition; adjusted EBITDA improved to $80.3M. Management projects 2026 revenues of $1.73–$1.84B, with four commercial products each targeting over $300M in annual net sales.
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Alkermes (ALKS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to earnings of $0.13 per share a year ago.
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade
The consensus price target hints at a 29.1% upside potential for Alkermes (ALKS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS
Abacus FCF Advisors LLC bought a new position in shares of Alkermes plc (NASDAQ: ALKS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 219,495 shares of the company's stock, valued at approximately $6,141,000. Abacus FCF Advisors LLC owned 0.13%
Avoro Capital Advisors LLC Trims Position in Alkermes plc $ALKS
Avoro Capital Advisors LLC reduced its holdings in Alkermes plc (NASDAQ: ALKS) by 22.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,240,000 shares of the company's stock after selling 660,000 shares during the period. Alkermes comprises 0.9% of Avoro Capital
